Autologous TAC-T Functional & Safety Profiling Services

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

The clinical translation of next-generation autologous T cell therapies faces critical challenges, including on-target off-tumor toxicity, uncontrolled cytokine release, and the precise characterization of their distinct "co-opting" biology. Creative Biolabs' Autologous TAC-T Functional & Safety Profiling service directly addresses these hurdles. We provide a rigorous suite of high-resolution, biologically-relevant assays designed to de-risk your therapeutic candidate. This enables you to definitively validate the efficacy and safety profile of your TAC-T constructs, accelerating a robust data package towards successful clinical development.

Introduction

Autologous TAC-T therapy is an innovative adoptive cell therapy where patient-derived T cells are genetically engineered with a T Cell Antigen Coupler to redirect their specificity against tumors via co-option of the endogenous TCR-CD3 complex. Our TAC-T Functional & Safety Profiling constitutes a critical preclinical evaluation suite, employing biologically-relevant, high-resolution assays to comprehensively characterize the therapy's cytotoxic potency, specificity, signaling fidelity, and safety profile prior to clinical translation.

Fig.1 TAC-T cell therapy: functional potency and toxicology analysis. (Creative Biolabs Original) Fig.1 Functional & safety assessment for autologous TAC-T cell therapy.

Our Services

Creative Biolabs provides a specialized suite of deliverables designed to validate the efficacy and safety of your T cell antigen coupler (TAC) constructs. We focus on the unique ability of TAC receptors to co-opt the endogenous TCR complex, providing a more controlled T cell response than traditional CAR-T therapies. Our profiling ensures that your lead candidates exhibit robust anti-tumor activity while maintaining a superior safety profile, specifically targeting solid tumor antigens.

Service Packages

Our Functional & Safety Profiling services deliver critical preclinical data packages through focused assays, ensuring robust TAC-T product efficacy and mitigating clinical risks.

Recursive Tumor Cell Killing Assay Service

This service provides a comprehensive assessment of the sustained cytotoxic potency of engineered TAC-T cells against tumor targets. We employ sequential co-culture assays to quantify their ability to engage in multiple rounds of tumor cell lysis, a key hallmark of therapeutic persistence. The analysis delivers critical data on T-cell activation kinetics, serial killing efficiency, and functional longevity. This profiling is essential for predicting in vivo efficacy, benchmarking candidate constructs, and supporting mechanism-of-action claims in regulatory submissions.

Controlled Cytokine Release Profiling Service

We offer precise characterization of the cytokine secretion profile of TAC-T cells following antigen-specific stimulation. The service evaluates the magnitude and spectrum of cytokine release, including key effector and inflammatory molecules, under controlled conditions. This analysis confirms the desired, target-dependent activation of the TAC-T cells while screening for potential hyperactivation or cytokine storm-related signatures. The resulting data is fundamental for understanding the product's mode of action, ensuring a favorable safety profile, and designing safe clinical dosing regimens.

Off-Target Reactivity Assessment Service

This service is designed to evaluate the specificity of TAC-T cell products and identify potential cross-reactivity with non-target tissues. Utilizing state-of-the-art methodologies, such as primary cell co-cultures and protein microarray screening, we assess reactivity against a broad panel of healthy human cells and antigens. The analysis provides a critical safety assessment to de-risk potential on-target/off-tumor or off-target toxicities, thereby strengthening the preclinical safety package and supporting investigational new drug application.

Our Service Process

Required Starting Materials: To proceed with the service, we require the submission of 2-3 essential components: the detailed TAC construct sequence, designated target-expressing cell lines, and/or primary donor PBMCs for autologous T cell generation.

Key Steps:

Workflow of autologous TAC-T functional & safety profiling services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will be provided with a detailed TAC-T Analytical Report that encompasses key analytical outcomes.

Key Advantages

Modular TAC Domain Profiling: We conduct independent functional evaluation of each molecular domain to systematically optimize overall construct design and therapeutic potential.
Bio-Native Signaling Validation: Our tailored assays assess critical intracellular phosphorylation events to confirm T-cell activation mirrors physiological signaling pathways.
Comprehensive Safety Screening: We implement customized high-resolution panels to quantify cytokine release profiles and systematically evaluate cross-reactivity risks across diverse human cell types.

FAQs

Q1: How does TAC-T functional and safety profiling differ from conventional CAR-T characterization assays?

A1: Conventional CAR-T assays primarily evaluate signaling and function through the synthetic scFv-CD3ζ axis. In contrast, our TAC-T profiling suite is uniquely designed to quantify the efficiency of your construct's CD3-binding domain in specifically recruiting the patient's endogenous TCR complex. This critical assessment verifies that T-cell activation leverages natural physiological pathways, thereby preserving intrinsic regulatory mechanisms and potentially mitigating risks associated with synthetic receptor overstimulation.

Q2: What is the core advantage of employing an autologous platform within your profiling services?

A2: The utilization of client-provided, patient- or donor-derived PBMCs is fundamental to our approach. This ensures that all functional and safety data, from potency to cytokine release, are generated within the context of the specific donor's T-cell repertoire and baseline fitness. Accounting for this natural variability provides a more clinically predictive dataset, which is essential for accurately forecasting real-world therapeutic efficacy and individual patient safety profiles during translational development.

Why Choose Us?

We deliver definitive, clinically-predictive data for TAC-T development. Our "Bio-native" platform uniquely validates your construct's integrated function by assessing its ability to correctly recruit the native TCR complex, mirroring physiological activation. Supported by published evidence demonstrating superior solid-tumor infiltration with reduced toxicity, our service de-risks your path to the clinic.

How to contact us?

Creative Biolabs provides the definitive Functional & Safety Profiling platform for TAC-T development, designed to advance the next generation of precision solid tumor therapies. We integrate deep domain expertise with cutting-edge clinical translation strategies to de-risk your development pathway and accelerate therapeutic candidates toward clinical validation.

To initiate a strategic collaboration or request a tailored proposal, please contact our dedicated scientific consultants.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.